Clinical Cancer Research, Vol 3, Issue 4 593-600, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas

A Makris, TJ Powles, M Dowsett, CK Osborne, PA Trott, IN Fernando, SE Ashley, MG Ormerod, JC Titley, RK Gregory and DC Allred
Breast Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, London, United Kingdom.

Our aim was to determine whether biological molecular markers can predict response to neoadjuvant chemoendocrine therapy in patients with early breast cancer. Ninety patients (median age 56 years; range, 28-69 years) with primary operable breast carcinoma were studied. They were treated with four 3-weekly cycles of chemotherapy with mitozantrone, methotrexate (+/- mitomycin C), and tamoxifen prior to surgery. Fine-needle aspiration was used to obtain samples from patients prior to therapy, and the following parameters were assessed: estrogen receptor (ER), progesterone receptor (PgR), p53, Ki67, Bcl-2, and c-erbB-2 measured by immunocytochemistry, and ploidy and S-phase fraction (SPF) by flow cytometry. The tumors of 78% of the subjects responded (complete response, 9%; partial response, 69%) and 22% did not (no change, 20%; progressive disease, 2%). Response rates according to disease stage and patient age were as follows: T1, 74%; T2, 79%; T3/T4, 78%; age </=50 years, 76%; >50, 79% (P = not significant). Response rates for other parameters were as follows: ER-positive, 82%, and -negative, 70%; PgR-positive, 86%, and -negative, 71%; p53-positive, 74%, and -negative, 81%; Bcl-2-positive, 85%, and -negative 61%; c-erbB-2-positive, 57%, and -negative, 93%; Ki67 high, 77%, and low, 81%; SPF high, 77%, and low, 77%; aneuploid, 71%; and diploid, 85%. Only the difference for c-erbB-2 was statistically significant (P = 0.007). A trend for higher response rates to neoadjuvant chemoendocrine therapy for tumors that were positive for ER, PgR, and Bcl-2 was observed but did not reach statistical significance. Tumors negative for c-erbB-2 had a higher response rate, which was statistically significant. In contrast, Ki67, ploidy, SPF, and p53 failed to predict for response.

This article has been cited by other articles:

				B. J. Chae, J. S. Bae, A. Lee, W. C. Park, Y. J. Seo, B. J. Song, J. S. Kim, and S. S. Jung p53 as a Specific Prognostic Factor in Triple-negative Breast Cancer Jpn. J. Clin. Oncol., April 1, 2009; 39(4): 217 - 224. [Abstract] [Full Text] [PDF]

				N. Tinari, R. Lattanzio, C. Natoli, E. Cianchetti, D. Angelucci, E. Ricevuto, C. Ficorella, P. Marchetti, S. Alberti, M. Piantelli, et al. Changes of Topoisomerase II{alpha} Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free Survival Clin. Cancer Res., March 1, 2006; 12(5): 1501 - 1506. [Abstract] [Full Text] [PDF]

				A. Urruticoechea, I. E. Smith, and M. Dowsett Proliferation Marker Ki-67 in Early Breast Cancer J. Clin. Oncol., October 1, 2005; 23(28): 7212 - 7220. [Abstract] [Full Text] [PDF]

				L. A. Newman and H. M. Kuerer Advances in Breast Conservation Therapy J. Clin. Oncol., March 10, 2005; 23(8): 1685 - 1697. [Full Text] [PDF]

				M. S. Mano and A. Awada Primary chemotherapy for breast cancer: the evidence and the future Ann. Onc., August 1, 2004; 15(8): 1161 - 1171. [Abstract] [Full Text] [PDF]

				L. G. Estevez and W. J. Gradishar Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer Clin. Cancer Res., May 15, 2004; 10(10): 3249 - 3261. [Abstract] [Full Text] [PDF]

				S. Geisler, A.-L. Borresen-Dale, H. Johnsen, T. Aas, J. Geisler, L. A. Akslen, G. Anker, and P. E. Lonning TP53 Gene Mutations Predict the Response to Neoadjuvant Treatment with 5-Fluorouracil and Mitomycin in Locally Advanced Breast Cancer Clin. Cancer Res., November 15, 2003; 9(15): 5582 - 5588. [Abstract] [Full Text] [PDF]

				H. Bonnefoi, S. Diebold-Berger, P. Therasse, A. Hamilton, M. van de Vijver, G. MacGrogan, L. Shepherd, N. Amaral, C. Duval, R. Drijkoningen, et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann. Onc., March 1, 2003; 14(3): 406 - 413. [Abstract] [Full Text] [PDF]

				S. De Placido, M. De Laurentiis, C. Carlomagno, C. Gallo, F. Perrone, S. Pepe, A. Ruggiero, A. Marinelli, C. Pagliarulo, L. Panico, et al. Twenty-year Results of the Naples GUN Randomized Trial: Predictive Factors of Adjuvant Tamoxifen Efficacy in Early Breast Cancer Clin. Cancer Res., March 1, 2003; 9(3): 1039 - 1046. [Abstract] [Full Text] [PDF]

				L. G. Estevez, J. M. Cuevas, A. Anton, J. Florian, J. M. Lopez-Vega, A. Velasco, F. Lobo, A. Herrero, and J. Fortes Weekly Docetaxel as Neoadjuvant Chemotherapy for Stage II and III Breast Cancer: Efficacy and Correlation with Biological Markers in a Phase II, Multicenter Study Clin. Cancer Res., February 1, 2003; 9(2): 686 - 692. [Abstract] [Full Text] [PDF]

				L. Assersohn, L. Gangi, Y. Zhao, M. Dowsett, R. Simon, T. J. Powles, and E. T. Liu The Feasibility of Using Fine Needle Aspiration from Primary Breast Cancers for cDNA Microarray Analyses Clin. Cancer Res., March 1, 2002; 8(3): 794 - 801. [Abstract] [Full Text] [PDF]

				S. Geisler, P. E. Lønning, T. Aas, H. Johnsen, O. Fluge, D. F. Haugen, J. R. Lillehaug, L. A. Akslen, and A.-L. Børresen-Dale Influence of TP53 Gene Alterations and c-erbB-2 Expression on the Response to Treatment with Doxorubicin in Locally Advanced Breast Cancer Cancer Res., March 1, 2001; 61(6): 2505 - 2512. [Abstract] [Full Text]

				R. Colomer, S. Montero, A. Lluch, B. Ojeda, A. Barnadas, A. Casado, B. Massutí, H. Cortés-Funes, and B. Lloveras Circulating HER2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer Clin. Cancer Res., June 1, 2000; 6(6): 2356 - 2362. [Abstract] [Full Text]

				A. C. Wolff and N. E. Davidson Primary Systemic Therapy in Operable Breast Cancer J. Clin. Oncol., April 7, 2000; 18(7): 1558 - 1569. [Abstract] [Full Text] [PDF]

				E. M. J. J. Berns, J. A. Foekens, R. Vossen, M. P. Look, P. Devilee, S. C. Henzen-Logmans, I. L. van Staveren, W. L. J. van Putten, M. Inganäs, M. E. M.-v. Gelder, et al. Complete Sequencing of TP53 Predicts Poor Response to Systemic Therapy of Advanced Breast Cancer Cancer Res., April 1, 2000; 60(8): 2155 - 2162. [Abstract] [Full Text]

				H. J. Mackay, D. Cameron, M. Rahilly, M. J. Mackean, J. Paul, S. B. Kaye, and R. Brown Reduced MLH1 Expression in Breast Tumors After Primary Chemotherapy Predicts Disease-Free Survival J. Clin. Oncol., January 5, 2000; 18(1): 87 - 87. [Abstract] [Full Text] [PDF]

				I. Bieche, P. Onody, I. Laurendeau, M. Olivi, D. Vidaud, R. Lidereau, and M. Vidaud Real-Time Reverse Transcription-PCR Assay for Future Management of ERBB2-based Clinical Applications Clin. Chem., August 1, 1999; 45(8): 1148 - 1156. [Abstract] [Full Text] [PDF]

				H. M. Kuerer, L. A. Newman, T. L. Smith, F. C. Ames, K. K. Hunt, K. Dhingra, R. L. Theriault, G. Singh, S. M. Binkley, N. Sneige, et al. Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy J. Clin. Oncol., February 1, 1999; 17(2): 460 - 460. [Abstract] [Full Text] [PDF]